Safety of sipavibart as a pre-exposure prophylaxis for COVID-19 in individuals at high risk of developing severe disease: results of the NOVELLA clinical study conducted in the Russian population
Aim. To evaluate the safety of sipavibart (AZD3152) for pre-exposure prophylaxis of COVID-19 in Russian population of participants at increased risk of developing severe COVID-19. Materials and methods. Randomized, double-blind phase 2 NOVELLA study included adults who had an increased risk of se...
Saved in:
| Main Authors: | Daria S. Fomina, Galina N. Salogub, Alexey L. Maslyanskiy, Galina I. Gridneva, Vadim V. Ptushkin, Maria Yu. Sitnikova, Oksana G. Ni, Valeriy V. Breder, Mariia S. Shustova, Nadezhda A. Kravtsova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2024-12-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/656021/171762 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season
by: Piero Poletti
Published: (2025-04-01) -
Humanized Antibodies. Modern Developments and Prospects for the Creation of Medical Protectors Against Biological Threads and Hazards
by: A. S. Gorshkov, et al.
Published: (2024-01-01) -
A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function
by: Wael Bahnan, et al.
Published: (2022-12-01) -
Immunotherapy for ulcerative colitis: targeting innate and adaptive immune responses for better clinical outcomes
by: Isha T. Shah, et al.
Published: (2025-07-01) -
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
by: Paul Loubet, et al.
Published: (2024-12-01)